The effects of zileuton and montelukast in reperfusion-induced arrhythmias in anesthetized rats

Current Therapeutic Research - Clinical and Experimental

Volumn 75, Issue , 2013, Pages 27-32

  Gonca, Ersöz ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Anesthetized rat; Ischemia reperfusion arrhythmia; Montelukast; Zileuton

Indexed keywords

DIMETHYL SULFOXIDE; MONTELUKAST; SODIUM CHLORIDE; ZILEUTON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART RATE; HEART VENTRICLE TACHYCARDIA; LEFT CORONARY ARTERY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; POWDER; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

EID: 84890161918     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2013.06.001     Document Type: Article

References (34)

1. Ugalde H., Ugalde D., Muñoz M. Angioplasty compared to thrombolysis as the initial reperfusion therapy in acute myocardial infarction. Rev Med Chil 2011, 139:1396-1402.
2. Piers S.R., Wijnmaalen A.P., Borleffs C.J., et al. Early reperfusion therapy affects inducibility, cycle length, and occurrence of ventricular tachycardia late after myocardial infarction. Circ Arrhythm Electrophysiol 2011, 4:195-201.
3. Tecder-Unal M., Kanzýk Y. Peroxynitrite in reperfusion arrhythmias and its whole blood chemiluminescence results. Pharmacol Res 2004, 49:7-16.
4. Said M., Becerra R., Valverde C.A., et al. Calcium-calmodulin dependent protein kinase II (CaMKII): a main signal responsible for early reperfusion arrhythmias. J Mol Cell Cardiol 2011, 51:936-944.
5. Dhein S., Schott M., Gottwald E., et al. The contribution of neutrophils to reperfusion arrhythmias and a possible role for antiadhesive pharmacological substances. Cardiovasc Res 1995, 30:881-888.
6. Wang Q.D., Pernow J., Sjöquist P.O., Rydén L. Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc Res 2002, 55:25-37.
7. Back M., Dahlen S.E., Drazen J.M., et al. International union of basic and clinical pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev 2011, 63:539-584.
8. Sasaki K., Ueno A., Katori M., Kikawada R. Detection of leukotriene B4 in cardiac tissue and its role in infarct extension through leucocyte migration. Cardiovasc Res 1988, 22:142-148.
9. Carry M., Korley V., Willerson J.T., et al. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 1992, 85:230-236.
10. Jordan J.E., Zhao Z.Q., Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999, 43:860-878.
11. Mastalerz L., Kumik J. Antileukotriene drugs in the treatment of asthma. Pol Arch Med Wewn 2010, 120:103-108.
12. Genovese T., Rossi A., Mazzon E., et al. Effects of zileuton and montelukast in mouse experimental spinal cord injury. Br J Pharmacol 2008, 153:568-582.
13. Isikdemir F., Kurcer Z., Dengiz G.O., et al. Effects of montelukast and zileuton on testicular torsion/detorsion injury in rats. Andrologia 2012 Nov 9, [Epub ahead of print].
14. Oral A., Odabasoglu F., Halici Z., et al. Protective effects of montelukast on ischemia-reperfusion injury in rat ovaries subjected to torsion and detorsion: biochemical and histopathologic evaluation. Fertil Steril 2011, 95:1360-1366.
15. Ozkan E., Yardimci S., Dulundu E., et al. Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res 2010, 159:588-594.
16. Patel N.S., Cuzzocrea S., Chatterjee P.K., et al. Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. Mol Pharmacol 2004, 66:220-227.
17. Ingelsson E., Yin L., Bäck M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol 2012, 129:702-707.
18. Chen S., Jin G., Shan J., Zhang M., Men Q., Xu L. Cardioprotective effect and influence on NOS expression of Montelukast sodium in rats. Yao Xue Xue Bao 2003, 38:821-825.
19. Kwak H.J., Park K.M., Choi H.E., et al. The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKC delta. Cell Signal 2010, 22:80-87.
20. Bozdogan O., Gonca E., Nebigil M., Tiryaki E.S. Effect of thimerosal on arrhythmia induced by coronary ligation: the involvement of ATP-dependent potassium channels. Int Heart J 2005, 46:711-722.
21. Walker M.J., Curtis M.J., Hearse D.J., et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischemia infarction and reperfusion. Cardiovasc Res 1988, 22:447-455.
22. Lepran I., Koltai M., Siegmund W., Szekeres L. Coronary artery ligation, early arrhythmias, and determination of the ischemic area in conscious rats. J Pharmacol Meth 1983, 9:219-230.
23. Sokołowska B., Dropinski J., Rzeszutko M., et al. Influence of leukotriene biosynthesis inhibition on heart rate in patients with atrial fibrillation. Int J Cardiol 2010, 145:625-626.
24. Kevin L.G., Novalija E., Stowe D.F. Reactive oxygen species as mediators of cardiac injury and protection: the relevance to anesthesia practice. Anesth Analg 2005, 101:1275-1287.
25. Antoons G., Willems R., Sipido K.R. Alternative strategies in arrhythmia therapy: evaluation of Na/Ca exchange as an anti-arrhythmic target. Pharmacol Ther 2012, 134:26-42.
26. Pagliaro P., Moro F., Tullio F., et al. Cardioprotective pathways during reperfusion: focus on redox signaling and other modalities of cell signaling. Antioxid Redox Signal 2011, 14:833-850.
27. Gök S., Banoaglu N. Effects of a leukotriene D4 receptor antagonist, L-648,051, and a dual inhibitor lypoxygenase and cyclooxygenase, BW-755C, on digoxin-induced arrhythmias in guinea-pigs. Arch Int Pharmacodyn Ther 1993, 321:72-80.
28. Haworth R.A., Potter K.T., Russell D.C. Role of arachidonic acid, lipoxygenase, and mitochondrial depolarization in reperfusion arrhythmias. Am J Physiol Heart Circ Physiol 2010, 299:165-174.
29. Kwak H.J., Park K.M., Choi H.E., et al. The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKC delta. Cell Signal 2010, 22:80-87.
30. Asano G., Takashi E., Ishiwata T., et al. Pathogenesis and protection of ischemia and reperfusion injury in myocardium. J Nippon Med Sch 2003, 70:384-392.
31. ATP channel blockage confer protection against ischemia/reperfusion induced arrhythmia in anesthetized male rats. J Cardiovasc Pharmacol Ther 2010, 15:403-411.
32. Das B., Sarkar C. Is preconditioning by oxytocin administration mediated by iNOS and/or mitochondrial K(ATP) channel activation in the in vivo anesthetized rabbit heart?. Life Sci 2012, 90:763-769.
33. Das B., Sarkar C. Similarities between ischemic preconditioning and 17 beta-estradiol mediated cardiomyocyte KATP channel activation leading to cardioprotective and antiarrhythmic effects during ischemia/reperfusion in the intact rabbit heart. J Cardiovasc Pharmacol 2006, 47:277-286.
34. Henderson W.R. The role of leukotrienes in inflammation. Ann Intern Med 1994, 121:684-697.